The irrigated, contact-force sensing catheter features alongside the TruPulse generator. Both offer full integration with the Carto 3 electro-anatomical mapping system.

Johnson & Johnson MedTech expects to have TruPulse generator hardware compatibility available in the first half of 2025. When fully approved, it expects the system to provide the ability to switch between RF and PF energy. The catheter remains investigational in the U.S.

Results from its SmartfIRE clinical trial presented in April demonstrated 100% acute procedural success during standard electrophysiology mapping and ablation procedures. That study looked at drug-refractory symptomatic paroxysmal AFib patients. Additionally, investigators said 96.8% of patients showed no acute reconnections in the veins.